Patrick Soon-Shiong
ฝัง
- เผยแพร่เมื่อ 25 พ.ค. 2024
- Dr Patrick Soon-Shiong, Chairman & CEO, NantWorks delivers his talk about his journey from medical student in South Africa in the 70's to the recent FDA approval of ANKTIVA, First-in-Class IL-15 Receptor Agonist for BCG- Unresponsive Non-Muscle Invasive Bladder Cancer. This was his first talk on the topic since the FDA approval and it was delivered remotely at the IMPC - Beyond the Genome Conference which took place in South Africa from 28 to 30 April 2024.
